Matthias Hegblom

“So firstly, on exudafimab, now with a confirmed favorable safety profile from the ongoing phase 2A testing in Parkinson's MSA patients. Sometimes the pushback around this asset is coming back to the fact that it's now roughly four years or somewhat more than four years that the asset was handed back to you.”